Could a 14-Day drug delay diabetes in toddlers?

NCT ID NCT05757713

Ongoing Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called teplizumab in 20 children under 8 who have early signs of type 1 diabetes (Stage 2). The goal is to check if the drug is safe and how the body handles it. Teplizumab works by calming the immune system to protect insulin-making cells. If successful, it might delay or prevent the need for insulin shots.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: teplizumab (a drug that calms the immune system)
What this could lead to: If it works, this could help delay or prevent full-blown type 1 diabetes in very young children.
What could go wrong: This is a small, early-phase study with only 20 kids, so results may not apply to everyone. Teplizumab can cause side effects like infections or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 1

Contacts and locations

Locations

Barbara Davis Center for Diabetes Site Number : 102

Aurora, Colorado, 80045, United States
Centricity Research Site Number : 104

Columbus, Georgia, 31904, United States
Children's Hospital of Philadelphia Site Number : 108

Philadelphia, Pennsylvania, 19104, United States
Indianapolis University Health Riley Hospital for Children Site Number : 110

Indianapolis, Indiana, 46202, United States
MulitCare Institute for Research & Innovation Site Number : 103

Tacoma, Washington, 98405, United States
Sanford Diabetes and Thyroid Clinic Site Number : 106

Sioux Falls, South Dakota, 57105, United States
UBMD Pediactrics Site Number : 105

Buffalo, New York, 14203, United States
UCSF Medical Center Site Number : 107

San Francisco, California, 94143, United States
Vanderbilt Univerity Medical Center Site Number : 109

Nashville, Tennessee, 37232, United States
Yale University School of Medicine Site Number : 101

New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.